What is the prevalence of Asherson’s Syndrome / Catastrophic Antiphospholipid Syndrome?
How many people does Asherson’s Syndrome / Catastrophic Antiphospholipid Syndrome affect? Does it have the same prevalence in men and women? And in the different countries?
Asherson’s Syndrome, also known as Catastrophic Antiphospholipid Syndrome (CAPS), is a rare autoimmune disorder characterized by the formation of blood clots in small blood vessels throughout the body. The prevalence of CAPS is estimated to be around 0.5 to 1 case per million people per year. It primarily affects young to middle-aged adults, with a slight male predominance. CAPS can be life-threatening, leading to multiorgan failure if not promptly diagnosed and treated. Early recognition and aggressive management are crucial for improving outcomes in individuals with this syndrome.
Asherson’s Syndrome, also known as Catastrophic Antiphospholipid Syndrome (CAPS), is a rare and severe autoimmune disorder characterized by the formation of blood clots in small blood vessels throughout the body. This condition primarily affects young to middle-aged adults, with a slight predominance in males.
Due to its rarity, the prevalence of Asherson’s Syndrome/CAPS is not well-established. However, it is estimated to occur in approximately 0.5-1% of individuals with antiphospholipid syndrome (APS), a more common autoimmune disorder characterized by the presence of antiphospholipid antibodies.
Asherson’s Syndrome/CAPS is a life-threatening condition that can lead to multiple organ failure if not promptly diagnosed and treated. The exact cause of this syndrome is still unknown, but it is believed to involve a combination of genetic and environmental factors.
Early recognition and aggressive treatment are crucial in managing Asherson’s Syndrome/CAPS. Treatment typically involves high-dose anticoagulation therapy, immunosuppressive drugs, and supportive care to prevent further clot formation and organ damage.
